



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

| | | |
|--------------------------------|--|-----------|
| Summary for ARTG Entry: | 351742 | Gluteneze |
| ARTG entry for | Medicine Listed | |
| Sponsor | Miasca Investments Pty Ltd | |
| Postal Address | PO Box 1786, Noosaville BC, QLD, 4566 Australia | |
| ARTG Start Date | 15/12/2020 | |
| Product Category | Medicine | |
| Status | Active | |
| Approval Area | Listed Medicines | |

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Gluteneze

| | | | |
|---------------------|-------------------------|-----------------------|------------|
| Product Type | Single Medicine Product | Effective Date | 15/06/2021 |
|---------------------|-------------------------|-----------------------|------------|

Permitted Indications

Decrease/reduce/relieve colic (wind/gas pain)
Decrease/reduce/relieve excess intestinal gas
Maintain/support healthy digestive system function
Maintain/support healthy digestion
Maintain/support digestion/assimilation of nutrients
Aid/assist digestion/breakdown of dietary fat
Aid/assist/helps digestion of fats/fatty acids/triglycerides/lipid
Aid/assist digestion of glucose/sugar/carbohydrates
Helps reduce occurrence of symptoms of medically diagnosed gluten sensitivity caused by inadvertent gluten ingestion
Maintain/support digestive system health
Decrease/reduce/relieve abdominal bloating/distention
Decrease/reduce/relieve abdominal cramping
Decrease/reduce/relieve abdominal feeling of fullness
Relieve digestive discomfort
Helps reduce occurrence of symptoms of food intolerance

Indication Requirements

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to individuals with coeliac disease or dermatitis herpetiformis.

Product presentation must not imply or refer to gastro oesophageal reflux disease.

Label statement: If symptoms persist, worsen or episodes become more frequent talk to your medical practitioner.

Product presentation must not imply or refer to serious allergic conditions such as anaphylaxis.

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Product presentation must not imply or refer to lowering blood lipids, blood fats and triglycerides.

Label statement: For use only in conjunction with a gluten-free diet.

Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.



Australian Government
Department of Health
Therapeutic Goods Administration

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

| | |
|-----------|--------------------|
| Amylase | 10 thousand DU |
| cellulase | 4 thousand CU |
| lipase | 40 LipU |
| protease | 31.25 Thousand HUT |

Other Ingredients (Excipients)

hypromellose
medium chain triglycerides
microcrystalline cellulose
purified water

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary